Sildenafil Tablet, Film Coated
Product Images NDC 31722-776

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 31722-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A line chart depicting estimated cumulative mortality rates (%) over time for three dosage groups labeled High dose, Medium dose, and Low dose. The vertical axis shows mortality rate percentages, and the horizontal axis indicates time units. At the top, the number of patients at risk for each dose group is listed across several time points. The chart displays stepwise increases in mortality rates, with the High dose group having the highest cumulative mortality over time, followed by Medium and Low dose groups.*

FDA Label Image

Figure3 (Figure3)

A chart illustrating fold change and 90% confidence intervals in the pharmacokinetic parameters of Sildenafil when co-administered with various interacting drugs. The chart compares changes in AUC, Cmax, INR, and bleeding time relative to each interacting drug alone, with recommendations on dose adjustment indicating mostly no dose adjustment is needed except coadministration with Ritonavir is not recommended.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting changes from baseline over weeks 4, 8, and 12 in a study comparing Sildenafil 40 mg TID, placebo, and Sildenafil 80 mg TID. The graph shows individual data points with error bars for each group across the three time points.*

FDA Label Image

Figure5 (Figure5)

A forest plot comparing placebo and Sildenafil 20 mg TID effects on baseline walk distance across various subgroups: etiology of pulmonary arterial hypertension, functional capacity class, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index. The plot displays mean differences with confidence intervals for each subgroup, illustrating treatment impact on 6-minute walk distance.*

FDA Label Image

Figure6 (Figure6)

A line graph comparing the percentage of subjects without a clinically worsening event over time in days for two groups: placebo and Sildenafil. The x-axis represents days from randomization (0 to 112), and the y-axis shows the percentage without events, ranging from 70% to 100%. The Sildenafil group maintains a higher percentage without events compared to placebo throughout the period.*

FDA Label Image

Figure7 (Figure7)

A line plot showing the mean change from baseline in meters over weeks 4, 8, and 12 of a study. The graph compares three Sildenafil dosages administered three times daily (1 mg, 5 mg, and 20 mg). Error bars indicate the standard error for each treatment at each visit up to week 12.*

FDA Label Image

Structure (Structure)

Chemical structure diagram depicting the molecular structure of sildenafil, showing connected rings and functional groups characteristic of this active pharmaceutical ingredient.*

FDA Label Image

Camber1

FDA Label Image

Camber2

FDA Label Image

Fig2

A chart showing fold changes and 90% confidence intervals in AUC and Cmax for various interacting drugs relative to Sildenafil alone, including atorvastatin, azithromycin, bosentan, cimetidine, erythromycin, Maalox, oral contraceptives, ritonavir, and saquinavir. The chart also presents dosing recommendations based on these interactions, such as 'no dose adjustment' and 'coadministration not recommended.'*

FDA Label Image

Image1

A line plot showing mean change from baseline in meters over a 12-week study for three Sildenafil dosing groups: 1 mg TID, 5 mg TID, and 20 mg TID. The x-axis represents weeks (4, 8, 12), and the y-axis shows the change from baseline. Error bars represent the standard error for each treatment at each time point.*

FDA Label Image

Label

Sildenafil Tablets USP 20 mg film coated oral tablets label by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-776-90, package count of 90 tablets, and includes storage instructions at 20° to 25°C. It also contains dosage and dispensing details, a barcode, and manufacturing information including a batch coding area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.